Health
Medicare GLP-1 pilot program excludes patients with FDA-approved conditions from $50 discount
Enrollees with conditions like Type 2 diabetes or sleep apnea are directed to standard Part D plans, where out-of-pocket costs remain significantly higher.
The short version
- Medicare's 18-month GLP-1 Bridge pilot program offers certain weight loss medications for $50 a month, but excludes enrollees who have medical conditions the FDA has already approved the drugs to treat, such as Type 2 diabetes or severe obstructive sleep apnea.
- Excluded patients are redirected to standard Medicare Part D plans, where copays for GLP-1 medications can still reach hundreds of dollars per month.
- KFF estimates that up to 3.8 million people qualify for the pilot program, with total program costs projected to range between $3.3 billion and $10 billion depending on participation rates.
Key facts
- Medicare launched an 18-month pilot program called the GLP-1 Bridge program to offer covered access to Wegovy, Zepbound KwikPen, and Foundayo for $50 a month.[NPR]
- The $50 monthly discount is restricted to patients using the medication solely for weight loss; individuals with FDA-approved qualifying conditions like Type 2 diabetes must seek coverage under standard Part D plans.[NPR]
- Part D copays for GLP-1 drugs often range from $200 to $600 or more per month, according to primary care physician Taylor Lacy.[NPR]
- Federal law historically bars Medicare from covering drugs prescribed exclusively for weight loss, leading to the creation of the short-term pilot program to assess potential long-term cost savings.[NPR]
- CMS spokesperson Timothy Foster reported that initial prior authorization requests are mostly processed in under 12 hours and thousands of beneficiaries have received medication.[NPR]
What remains uncertain
- The ultimate cost of the pilot program to Medicare remains unknown, though KFF estimates range from $3.3 billion to $10 billion depending on enrollee uptake.[NPR]